olaparib: predicting response in breast cancer
Published 6 years ago • 164 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
5:43
using olaparib in gbrca1/2 breast cancer
-
1:10
dr. tripathy on impact of olaparib approval in brca-positive breast cancer
-
0:49
dr. tung discusses the role of olaparib in breast cancer
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
2:21
dr. rafii discusses clinical outcomes with olaparib in patients with ovarian cancer
-
2:46
dr. brufsky on the fda approval of olaparib in brca breast cancer
-
8:41
parp inhibitors for ovarian cancer: use of olaparib
-
3:31
distinguishing between parp inhibitors in breast cancer
-
6:18
value of olaparib in brca-mutated advanced ovarian cancer
-
2:19
phase iii results of olaparib for brca breast cancer
-
1:29
significant factors of clinical outcomes with olaparib in patients with ovarian cancer
-
7:42
parp inhibitors in other subtypes of breast cancer
-
9:13
tbcrc 048: olaparib monotherapy in metastatic breast cancer
-
11:22
olaparib in ovarian cancer
-
1:05
predictors of response to olaparib: looking beyond brca
-
3:05
exploring the use of olaparib in advanced breast cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
2:00
dr. zakashansky on the benefit of maintenance olaparib in brca ovarian cancer
-
6:03
olaparib maintenance for recurrent ovarian cancer